MPN Research Foundation

Home
United States
Chicago, IL
MPN Research Foundation

Patient-centric foundation that exists to fund research & improve outcomes for those living with MPNs Driving groundbreaking research. Improving lives.

Founded by patients for patients, MPN Research Foundation is a catalyst for research funding in pursuit of new treatments – and eventually a cure – for polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms (MPNs). To date, we have funded more than $18 million in MPN research. Through a combination of MPN cancer research, advocacy and education, we bring together patients, researchers, and clinicians around the common goal of realizing new treatment options and ultimately, a cure for MPNs.

03/31/2026

The March edition of Under the Microscope will hit your inboxes at 5PM CT today!

This digest includes:

👉 Patient Profile: Dr. Janeana White
👉 Clinical Update: New NCCN guidance on interferon in essential thrombocythemia (ET)
👉 Updated You and MPN modules Announcement
and more!

Join our community today to receive these stories and so much more with this link: https://f.mtr.cool/enzavtfyro

03/30/2026

We’re excited to share THREE new “You and MPN” education modules, now covering essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).

Explore the newly expanded You and MPN program — a multimedia learning experience built to make myeloproliferative neoplasm (MPN) science easier to follow and talk about with your care team.

Through animations, expert videos, and real patient stories, each module is designed to build confidence as you navigate your diagnosis.

Explore the program and share it with someone who might need it: https://f.mtr.cool/rqpssclxlr

In partnership with Mechanisms in Medicine.

You and MPN is made possible through independent educational grants from Disc Medicine, GSK, Incyte, Merck, PharmaEssentia, Sumitomo Pharma, and Takeda.

03/20/2026

Our new MPN PROGRESSion Registry™ is open for enrollment. This patient-focused research initiative gathers comprehensive myeloproliferative neoplasm (MPN) patient health data over 5-10 years. The goal is to help provide a better understanding of MPNs and why they can progress from one disease to another, or more rarely, to secondary acute myeloid leukemia (sAML).

This exciting milestone in the quest to slow, stop, or reverse that progression is made possible, in part, due to support from our industry partners.

🌟 A heartfelt thank you to , our newest MPN PROGRESSion Registry™ sponsor. Their backing helps make this groundbreaking research possible, and we are very appreciative! 🌟
___________________

If you're 18 or older, live in the U.S., and have ever been diagnosed with an MPN, joining is fast, easy, and secure.

👉 Enroll today: https://f.mtr.cool/iyxuroiwrc

03/19/2026

We are proud to congratulate Dr. Ann Mullaly and colleagues on the publication of an important new study examining TP53-mutated myeloproliferative neoplasms (MPNs). This large, multi-institutional effort brings new clarity to a question many patients and clinicians face — why TP53 mutations lead to aggressive disease in some people, but not in others.

In this study by Rolles et al., the researchers analyzed data from more than 1,500 people with MPNs and developed a new way to better identify who may be at higher risk for disease progression. The researchers identified three key factors that matter in TP53-mutated MPNs: bone marrow scarring (fibrosis), the number of mutations to the TP53 gene, and how strongly the types of mutations to TP53 are affecting the cell’s activity. Together, these factors inform a new risk model that may help identify who needs closer monitoring and who may have a more stable disease course.

This kind of insight is essential for improving prognosis and personalized care in rare blood cancers.

MPN Research Foundation is honored to have supported this work by funding MPN data entry into the Hematologic Malignancy Data Repository at Dana-Farber Cancer Institute , which made this type of large, collaborative analysis possible. This study reflects what your support makes possible — advancing research improved prognosis, design smarter clinical trials, and move closer to more informed care for people living with MPNs.

We celebrate this milestone with the investigators and the entire research community working to improve outcomes for patients worldwide. Learn more here: https://f.mtr.cool/eoidznofkc

03/10/2026

One week left to register!

Don’t miss our next MPN Pathways: Empowered Voices in Research webinar, “Informed Consent,” happening Thursday, March 19 from 4-5pm CT.

Featuring Emily Largent, JD, PhD, RN, a leading bioethics scholar whose work focuses on human subjects research and the ethics of translating research to human care.

Learn how informed consent protects clinical trial participants, and how patient and caregiver perspectives help strengthen the process.

This webinar also counts toward completing the MPN Research Foundation Research Advocate Certification.

Can’t make it live? All registrants receive recording and post-session materials.

Register now: https://f.mtr.cool/osjkczusfq

03/09/2026

This is your final reminder, MPN community 💙

The 2026 MPN Patient Unmet Needs Assessment closes March 18, and your voice matters.

Whether this is your first time — or you participated in 2024 — your experience helps guide future research, education, and advocacy for myeloproliferative neoplasm (MPN) patients around the world.

🕒 Takes about 25 minutes

👉 Complete the assessment now: https://f.mtr.cool/itdfounaxz

Please consider sharing with other MPN patients so every voice is heard.

03/07/2026

Nurse knowledge is power. Sharing it is impact.

As a nurse who cares for patients living with myeloproliferative neoplasms (MPNs) and navigating the possibilities of disease progression, your role is critical.

Not only in delivering care, but in guiding patients through decisions that affect their long-term health and well-being. Your expertise and empathy help your MPN patients feel in control — even when questions and worries about disease progression make things feel uncertain.

Help share an opportunity with your eligible patients that empowers them and lets them contribute directly to future MPN research: the MPN PROGRESSion Registry™. Anyone 18 or older, living in the U.S., who has ever been diagnosed with an MPN can enroll.

👉 Learn more. Link in comments.

03/03/2026

The 2026 MPN Patient Unmet Needs Assessment is now open — and your experience helps guide future research, education, and advocacy for patients around the world.

If you participated in 2024, your input again is especially valuable. If not, we’d love to hear from you.

🕒 About 25 minutes
📅 Open until March 18, 2026

👉 Take the assessment today: https://f.mtr.cool/rcyyhkwvxr

Please share with other myeloproliferative neoplasm (MPN) patients, especially those outside the U.S., so every voice is heard.💙

03/01/2026

Today is Rare Disease Day! Thanks to our incredible community, we’ve raised over $77,000 to advance MPN research.

Your generosity helps us continue our over 25-year legacy of fueling scientific progress, supporting early discoveries, and bringing new treatments from bench to bedside.

If you haven’t joined in yet, it’s not too late! Every gift matters.

👉 Donate here: https://f.mtr.cool/rwbhfqilhf

Thank you for standing with the MPN community today.

02/27/2026

You’re a myeloproliferative neoplasm (MPN) patient living in the U.S. and have been thinking about enrolling in the MPN PROGRESSion Registry™. But you want to know: Can it be trusted? Will my data be safe?

The MPN PROGRESSion Registry™ is committed to protecting your privacy and ensuring your data is secure in many ways.🔒

Swipe to learn more.

02/26/2026

Unlock vital info on myeloproliferative neoplasms (MPNs) with our You and MPN Animated Patient Guide! This free, patient-focused program explains MPN types, risk factors, symptoms, diagnosis, and treatment using easy-to-understand animation, video, and infographic resources – created for patients and caregivers.

Explore the program at https://f.mtr.cool/kigagqbqxa

02/24/2026

Did you know? 95% of rare diseases lack FDA-approved treatments.

Clinical trials are the bridge from bench to bedside, but most patients never hear about them.

Our 2024 Patient & Caregiver Unmet Needs Assessment revealed:
✔ Only 10% of patient respondents reported participating in a trial
✔ 71% said their provider never discussed trial options

Your gift helps connect myeloproliferative neoplasm (MPN) patients to life-changing clinical trials through spreading knowledge to community hematologists and oncologists. We have also partnered with Blood Cancer United to give a more personalized approach to finding the right clinical trial for a patient.

This , stand for equity and access.
👉 Donate: https://f.mtr.cool/pcnkqtoxtu
👉 Explore trials: https://f.mtr.cool/abdbymqrzr

Address

PO Box 10743
Chicago, IL
60610

Website

http://www.mpnresearchfoundation.org/

Alerts

Be the first to know and let us send you an email when MPN Research Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MPN Research Foundation:

Shortcuts

Want your practice to be the top-listed Clinic in Chicago?